Key statistics
On Monday, Bio-Techne Corp (TE1:FRA) closed at 68.00, -13.38% below its 52-week high of 78.50, set on May 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 68.00 |
---|---|
High | 68.00 |
Low | 68.00 |
Bid | 70.50 |
Offer | 71.00 |
Previous close | 68.00 |
Average volume | 146.29 |
---|---|
Shares outstanding | 158.89m |
Free float | 157.24m |
P/E (TTM) | 75.82 |
Market cap | 11.33bn USD |
EPS (TTM) | 0.9402 USD |
Annual div (ADY) | 0.2986 EUR |
---|---|
Annual div yield (ADY) | 0.44% |
Div ex-date | Nov 08 2024 |
Div pay-date | Nov 22 2024 |
Data delayed at least 15 minutes, as of Nov 25 2024 08:23 GMT.
More ▼
Press releases
- Gemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum (FBS) Product Rights and Inventory from Bio-Techne
- BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES
- BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH
- BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO
- UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS
- BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS
- BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES
- ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at the Baylor College of Medicine's Center for Cell and Gene Therapy
- BIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING
- LUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH
More ▼